Lophius Biosciences Expands its Management Team and Prepares for Market Entry at the Beginning of 2012
News Jul 12, 2011
Lophius Biosciences, has announced the expansion of its existing management team. In addition to its CEO, Dr. Michael Lutz, the CSO and cofounder Dr. Ludwig Deml, and the cofounder and Head of the Business Development, Dr. Nadja Prang, Lophius Biosciences will supplement its experienced management team with the following people:
Ms. Sabine Wahlländer, the new Head of Sales & Marketing, has a Master degree of Ecotrophology and has more than 20 years of experience in the marketing and sales sector in the Life Science Industry.
After working in several managerial positions with increasing responsibility in the pharmaceutical and medical products industry, she became General Manager of Digene GmbH and successfully established the innovative Hybrid Capture HPV-Test on the German-speaking markets and in the Benelux countries.
Dr. Hämmerle, the new Head of Technical Operations, received his doctorate in the field of biochemistry and has more than 10 years of professional experience in managerial positions in research and development at biotechnical companies.
Dr. Hämmerle was Managing Director at Meltec GmbH since 2005, where he was responsible for product development and production transfer including the CE Certification of an automated microscope.
Dr. Karl Kleine, the new Head of Quality Management, has a PhD in chemistry and has many years of professional experience in managerial positions in bioinformatics and quality management. Dr. Kleine was strongly involved in the establishment of former Epidauros Biotechnologie AG as the world’s leading pharmacogenetic research organization.
Subsequent to the takeover of Epidauros by Clinical Data Inc. in 2007, Dr. Kleine was also responsible for worldwide quality management of Clinical Data´s genomic service subsidiary Cogenics Inc.
Dr. Kornelia Schlombs, the new Scientific Project Manager for Molecular Biology has a PhD in biochemistry and has comprehensive knowledge in the fields of molecular biology and genetics. Moreover, she has more than 12 years of experience in the biotechnology industry.
From 2005 to 2010 Ms. Dr. Schlombs was employed by former Epidauros Biotechnologie AG, where she started as a Study Director for Genotyping Studies in accordance with GLP. In her last position she worked as the department head in charge of all laboratory genotyping work. At Lophius Biosciences her area of responsibility encompasses product development on the basis of the patented Reverse T-Cell technology.
Dr. Sascha Barabas, the new Scientific Project Manager for Cell Biology and Immunology, has an MA and a PhD in biology and, in cooperation with Dr. Deml, worked out the immunological principles of the patented UREA technology in the scope of his doctorate at the Institute for Medical Microbiology and Hygiene in the Regensburg University Hospital.
Since his move to Lophius Biosciences, he has focused his efforts on appropriate product developments of the diagnostic test systems for T-Track® CMV and EBV.
The team is completed by Dr. Zanker from MedicalDevice+, an experienced expert in the field of regulatory affairs for diagnostic products.
“We are delighted to have put together such an extremely experienced and effective team with these additional team members. Our current plans foresee to complete our first product development in the field of transplantation as CE-certified tests by the end of 2011. As a result of our ongoing expansion of, above all, our sales and marketing organisation, we will be able to efficiently approach the product introduction with emphasis on the German-speaking markets then from the beginning of 2012”, said Dr. Michael Lutz, CEO of Lophius Biosciences.
WHO welcomes the Government of Malawi’s launch of the world’s first malaria vaccine today in a landmark pilot programme. The country is the first of three in Africa in which the vaccine, known as RTS,S, will be made available to children up to 2 years of age; Ghana and Kenya will introduce the vaccine in the coming weeks.READ MORE